Pharma

Hovione Names António Almeida and Marco Gil Co-CEOs as Jean-Luc Herbeaux Steps Down on 21 May After Three-Year Run — Both Incoming Executives Carry 19-Year Tenures and the Permanent CEO Search Is Already Open

Hovione, Portugal's flagship pharmaceutical contract-development-and-manufacturing group, will replace Jean-Luc Herbeaux with a two-person co-CEO bridge on 21 May 2026. António Almeida (CFO) and Marco Gil (SVP Sales & Marketing) take the top job jointly; both joined Hovione in 2007.

12 May 2026

Clinical Trial Volunteers in Portugal Keep Getting Their Medicine Free After the Study Ends, Until the SNS Can Supply It, Under an Ordinance in Force From Saturday

Bial Shelves the BIA 28-6156 Parkinson Phase 2 Trial After the Trofa Pharma Reads No Efficacy Signal at the Primary Endpoint — Five-Year Disease-Modification Programme Folded as the Compound Misses Its Placebo Comparator

Hovione Names António Almeida and Marco Gil Co-CEOs as Jean-Luc Herbeaux Steps Down on 21 May After Three-Year Run — Both Incoming Executives Carry 19-Year Tenures and the Permanent CEO Search Is Already Open

Farminveste's 2025 Net Profit Quintuples to €58.7 Million on the Alloga Logifarma Divestment — €908.6 Million Revenue, €51.6 Million EBITDA as the ANF-Controlled Holding Reweights Around Glintt, CUF and HMR International